期刊
WORLD JOURNAL OF CLINICAL CASES
卷 3, 期 1, 页码 42-51出版社
BAISHIDENG PUBLISHING GROUP INC
DOI: 10.12998/wjcc.v3.i1.42
关键词
Human epidermal growth factor receptor 2; Gastric cancer; Targeting therapy; Trastuzumab
资金
- KAKENHI [23390329]
- National Cancer Center Research and Development Fund [23-A-9]
Recent advances in molecular targeted therapies, including targeting human epidermal growth factor receptor 2 (HER2), had a major forward step in the therapy for gastric cancer patients. Application of HER2-targeted therapies, in particular trastuzumab in combination with chemotherapy in metastatic HER2-positive gastric cancers, resulted in improvements in response rates, time to progression and overall survival. Nevertheless, as with breast cancer, many patients with gastric cancer develop resistance to trastuzumab. Several promising therapies are currently being developed in combination with chemotherapy to increase the efficacy and overcome the cancer-resistance. Here we review the current overview of clinical application of agents targeting HER2 in gastric cancer. We also discuss the ongoing trials supporting the use of HER2-targeted agents combined with cytotoxic agents or other monoclonal antibodies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据